Chemogenetic ubiquitin E1 inhibitor TAK-243 CRISPR screen uncovers HAPSTR1/HUWE1 axis in chromatin proteostasis and cell cycle control
In this study, we sought to comprehensively map ubiquitin signaling networks at the crossroads of cellular proliferation and proteostasis, both crucial in cancer. Genome-wide CRISPR knockout screening in the presence of the ubiquitin E1 inhibitor TAK-243 identified 239 genes whose ablation sensitizes cells to ubiquitination blockade. Follow-up studies reveal a role for the nuclear protein, C16orf72/HECT, UBA, and WWE domain containing E3 ubiquitin protein ligase 1 (HUWE1)-Associated Protein modifying Stress Responses (HAPSTR1), in chromatin proteostasis and DNA replication. We show that HAPSTR1 recruits the E3 ligase HUWE1 to the chromatin, keeping the chromatin-associated proteome in check, and is itself turned over by HUWE1 during cell cycle progression. Structural modeling of the HAPSTR1/HUWE1 complex, supported by mutational analysis, demonstrates that loss of HUWE1 binding renders HAPSTR1 unable to support cellular proliferation when ubiquitin signaling is suppressed. Consequently, HAPSTR1 ablation impairs clearance of chromatin-associated proteins, triggering global transcriptional and proteostatic adaptations. Under diminished ubiquitin signaling, these adaptive mechanisms give way to replication stress and premature S phase entry, culminating in cell cycle collapse and DNA damage. Our findings uncover protein networks exhibiting synthetic lethality with ubiquitin signaling blockade and highlight vulnerabilities of actively proliferating cells to proteostatic imbalance at the chromatin.
Authors
- Martijn S. Luijsterburg (ORCID: https://orcid.org/0000-0001-5796-6541)
- Peter A. van Veelen (ORCID: https://orcid.org/0000-0002-7898-9408)
- Maja Vukić (ORCID: https://orcid.org/0000-0002-7555-7706)
- Amina F.A.S. Teunisse (ORCID: https://orcid.org/0000-0001-8870-3808)
- Linda Clijsters (ORCID: https://orcid.org/0000-0002-3118-9702)
- İdil Kirdök (ORCID: https://orcid.org/0000-0002-6325-9218)
- Arnoud H. de Ru (ORCID: https://orcid.org/0009-0002-1166-4059)
- Ilana Berlin (ORCID: https://orcid.org/0000-0001-7917-1475)
- Ilona J. de Graaf (ORCID: https://orcid.org/0000-0003-4957-2424)
- Klaas de Lint (ORCID: https://orcid.org/0000-0001-7134-444X)
- Sidrit Uruci (ORCID: https://orcid.org/0000-0003-3248-7960)
- Alfred C.O. Vertegaal (ORCID: https://orcid.org/0000-0002-7989-0493)
- Martina Wirth (ORCID: https://orcid.org/0000-0002-3210-8644)
- Vyacheslav Akimov (ORCID: https://orcid.org/0000-0002-8377-1761)
- Rob M.F. Wolthuis (ORCID: https://orcid.org/0000-0002-3109-1588)
- Lucia Daxinger (ORCID: https://orcid.org/0000-0001-6557-6201)
- Blagoy Blagoev (ORCID: https://orcid.org/0000-0002-3596-0066)
- Nila K. van Overbeek (ORCID: https://orcid.org/0000-0002-0431-3595)
Institutions
- University of Southern Denmark (DK)
- Leiden University Medical Center (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Science Advances
- Published
- 2026-10-16
- DOI
- https://doi.org/10.1126/sciadv.aea3388
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Danmarks Grundforskningsfond
- ZonMw
- Ministerie van Onderwijs, Cultuur en Wetenschap
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Novo Nordisk Fonden
- H2020 European Research Council